Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-Like Peptide-1 Receptor Agonist-Based Agents and Body Composition: Filling More Gaps.

Obesity (Silver Spring, Md.)·2026
Same author

Reference method matters: DXA system differences influence agreement with 3D optical imaging body composition estimates.

International journal of obesity (2005)·2026
Same author

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same author

Lipid metabolism of hepatocyte-like cells supports intestinal tumor growth in Drosophila.

Nature communications·2026
Same author

A dietary switch promotes sensory neuron-dependent cancer-associated cachexia.

Science (New York, N.Y.)·2026
Same author

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.

Science advances·2026

Related Experiment Video

Updated: Jun 2, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K

Call to Improve Coding of Cancer-Associated Cachexia.

Marcus D Goncalves1, Richard F Dunne2, Amy C Moore3

  • 1NYU Langone Health, New York, NY.

JCO Oncology Practice
|January 13, 2025
PubMed
Summary

Accurate diagnosis and coding of cancer cachexia are crucial but challenging due to lack of standardized care and overlapping symptoms. Improving these aspects will enhance patient care and advance treatments.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

1.7K

Related Experiment Videos

Last Updated: Jun 2, 2025

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

16.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:49

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer

Published on: February 10, 2023

1.7K

Area of Science:

  • Oncology
  • Metabolic Medicine

Background:

  • Cachexia, a systemic wasting syndrome in cancer patients, severely impacts quality of life, healthcare costs, and treatment outcomes.
  • Despite its prevalence and clinical significance, cachexia is frequently underdiagnosed and lacks formal coding, hindering effective management and research.
  • Impediments to diagnosis include a lack of standardized therapies, insufficient incentives for accurate coding, and overlapping clinical features with other conditions.

Purpose of the Study:

  • To identify and address the barriers to accurate diagnosis and coding of cancer cachexia.
  • To differentiate cachexia from related conditions such as unintentional weight loss, sarcopenia, frailty, and protein-calorie malnutrition.
  • To propose a framework for improving cachexia diagnosis and coding to facilitate better patient care and therapeutic development.

Main Methods:

  • Review of existing literature on cachexia diagnosis and coding challenges.
  • Comparative analysis of clinical features distinguishing cachexia from similar conditions.
  • Development of a proposed approach for enhancing diagnostic accuracy and coding practices.

Main Results:

  • Identified key diagnostic and coding impedances including lack of standardized treatments and coding incentives, and symptom overlap.
  • Delineated distinct clinical features and inter-relations between cachexia and conditions like sarcopenia and malnutrition.
  • Proposed a structured approach to improve cachexia diagnosis and coding.

Conclusions:

  • Enhanced diagnostic accuracy and coding for cachexia are essential for improving patient identification, stratification, and management.
  • This improved framework will support the development of mechanism-based therapies and facilitate the approval of advanced treatments by regulatory bodies like the US Food and Drug Administration.
  • Addressing diagnostic and coding challenges is critical for advancing the field of cachexia research and clinical care.